Literature DB >> 3204515

Characterization of an "in vitro" blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs.

J B van Bree1, A G de Boer, M Danhof, L A Ginsel, D D Breimer.   

Abstract

The in vitro blood-brain barrier model described consisted of confluent monolayers of bovine cerebrovascular cells in primary cultures. Aim of the study was to investigate whether this type of model exhibits transport characteristics comparable to the in vivo blood-brain barrier and whether the cells in the cultured monolayers were able to form tight junctions, the most typical feature of the in vivo blood-brain barrier. Endothelial permeability of fluorescein-conjugated dextrans with increasing molecular size was correlated to monolayer pore shape, size and abundance by means of a mathematical model. Results showed that the in vitro pores had a longitudinal appearance with an effective pore size of 81 A and fractional pore area of 0.04%. These data indicate that the properties of the in vitro pores and in vivo tight junctions are comparable. The monolayer model was applied successfully to establish a relationship between endothelial permeability and drug lipophilicity, using several beta blocking agents and nonsteroidal anti-inflammatory drugs as model drugs. Results showed a sigmoidal relationship between these parameters, indicating the existence of a threshold lipophilicity for passive transendothelial transport.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3204515

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  35 in total

1.  A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children.

Authors:  B J Anderson; G A Woollard; N H Holford
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 2.  Drug transport across the blood--brain barrier. I. Anatomical and physiological aspects.

Authors:  J B Van Bree; A G De Boer; M Danhof; D D Breimer
Journal:  Pharm Weekbl Sci       Date:  1992-10-16

3.  The effect of protein binding on ivermectin uptake by bovine brain microvessel endothelial cells.

Authors:  K L Audus; S R Knaub; F L Guillot; J M Schaeffer
Journal:  Vet Res Commun       Date:  1992       Impact factor: 2.459

Review 4.  Drugs and brain death.

Authors:  M Kennedy; N Kiloh
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 5.  Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology.

Authors:  Máiria A Deli; Csongor S Abrahám; Yasufumi Kataoka; Masami Niwa
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

6.  Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier.

Authors:  Carola Förster; Malgorzata Burek; Ignacio A Romero; Babette Weksler; Pierre-Olivier Couraud; Detlev Drenckhahn
Journal:  J Physiol       Date:  2008-02-07       Impact factor: 5.182

Review 7.  Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research.

Authors:  Céline Passeleu-Le Bourdonnec; Pierre-Alain Carrupt; Jean Michel Scherrmann; Sophie Martel
Journal:  Pharm Res       Date:  2013-06-26       Impact factor: 4.200

8.  Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux.

Authors:  D Groenendaal; J Freijer; D de Mik; M R Bouw; M Danhof; E C M de Lange
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

9.  Insoluble powder formulation as an effective nasal drug delivery system.

Authors:  Fusashi Ishikawa; Mika Murano; Minoru Hiraishi; Toshikazu Yamaguchi; Ikumi Tamai; Akira Tsuji
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

10.  SPION-enhanced magnetic resonance imaging of Alzheimer's disease plaques in AβPP/PS-1 transgenic mouse brain.

Authors:  Laurel O Sillerud; Nathan O Solberg; Ryan Chamberlain; Robert A Orlando; John E Heidrich; David C Brown; Christina I Brady; Thomas A Vander Jagt; Michael Garwood; David L Vander Jagt
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.